Core Viewpoint - Eton Bio (06998) shares rose nearly 9% at the close, currently up 6.88% at HKD 2.95, with a trading volume of HKD 3.5091 million following the announcement of the completion of the first dosing in a Phase II clinical trial for the new drug EDP167 targeting homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - Eton Bio announced that the Phase II clinical trial for EDP167 has commenced, focusing on adult patients with homozygous familial hypercholesterolemia [1] - The primary endpoint of the trial is the change in LDL-C levels from baseline after 24 weeks of treatment, with results expected by Q4 2026 [1] - The company underwent a reverse merger with Jiahe Biotechnology, marking the official establishment of Eton Bio and a new phase in strategic integration and development [1] Group 2 - The Chinese stock name for Jiahe Biotechnology has been changed from "Jiahe Biotechnology" to "Eton Bio," effective from 9:00 AM on February 6, 2026 [1]
亿腾嘉和尾盘涨近9% 旗下EDP167临床II期研究成功完成首例受试者给药